Summary
Glipizide is a sulfocyclohexylurea with proven antidiabetic properties. Glipizide treated patients have been compared during an initial period of three months with three groups of comparable patients receiving single agent therapy, viz. glibenclamide, chlorpropamide, or phenformin. The drug seems to be an easy-to-handle antidiabetic agent, active in a dosage from 2.5 to 20 mg in patients with maturity-onset diabetes, not satisfactorily controlled on diet alone. The frequency of primary failures was slightly higher than with glibenclamide and chlorpropamide, but on the contrary the tolerance was better and the side effects negligible.
Article PDF
Similar content being viewed by others
Avoid common mistakes on your manuscript.
References
Ambrogi, V., Bloch, K., Daturi, S., Griggi, E., Logemann, W., Parenti, M.A., Rabini, T., Tommasini, R.: New oral antidiabetic drugs. Part I. Arzneimittel-Forsch.21, 200–204 (1971)
Ambrogi, V., Bloch, K., Cozzi, P., Daturi, S., Logemann, W., Parenti, M.A., Tommasini, R.: New oral antidiabetic drugs. Part II. Arzneimittel-Forsch.21, 204–208 (1971)
Marigo, S., Del Nevo, G., Dinni, P.P., Sacchetti, G.: Pharmacological methods for evaluating a new hypoglycemic agent in humans. Arzneimittel-Forsch.21, 215–220 (1971)
Pedrazzi, E., Pisani-Cerretti, A., Losi, S., Bommartini, E., Artini, D., Emanueli, A.: Evaluation in hospitalised subjects of a new hypoglycemic sulfonylurea: glidiazinamide. Arzneimittel-Forsch.21, 220–225 (1971)
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
De Leeuw, I., De Baere, H., Decraene, P. et al. An open comparative study of the efficacy and tolerance of a new antidiabetic agent: Glipizide. Diabetologia 9 (Suppl 1), 364–366 (1973). https://doi.org/10.1007/BF01218448
Received:
Revised:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF01218448